|
|
|
|
| LEADER |
03878nam a2200325 u 4500 |
| 001 |
EB001029790 |
| 003 |
EBX01000000000000000823343 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150411 r ||| eng |
| 100 |
1 |
|
|a Coeytaux, Remy R.
|
| 245 |
0 |
0 |
|a ECG-based signal analysis technologies
|h Elektronische Ressource
|c Remy R. Coeytaux, John W. Williams, Jr., Eugene Chung, S. Michael Gharacholou
|
| 260 |
|
|
|a Rockville, Maryland
|b Agency for Healthcare Research and Quality
|c 2010, May 24, 2010
|
| 300 |
|
|
|a 1 PDF file (70 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Electrocardiography / methods
|
| 700 |
1 |
|
|a Williams, John W.
|e [author]
|
| 700 |
1 |
|
|a Chung, Eugene
|e [author]
|
| 700 |
1 |
|
|a Gharacholou, S. Michael
|e [author]
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a Duke University Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Technology assessment report
|
| 500 |
|
|
|a Title from PDF title page. - "Project ID: CRDD1008."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK253988
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a In patients where CAD is suspected - either because of the presence of risk factors for CAD or because of symptoms that may represent manifestations of CAD (e.g., chest pain) - the standard electrocardiogram (ECG) is one of the most commonly performed tests. The ECG is nearly universally available, noninvasive, easy to perform, relatively inexpensive, and can usually be completed in less than 10 minutes. However, a resting ECG has limited sensitivity for detecting CAD. New devices that seek to improve ECG capabilities have been proposed - specifically, devices that are potentially capable of detecting significant CAD or myocardial ischemia. An enhanced ECG-based test might demonstrate greater positive or negative predictive values, thereby limiting the harms associated with delays in treatment, or providing the diagnostic information necessary to avoid invasive diagnostic or therapeutic interventions.
|
| 520 |
|
|
|a The Coverage and Analysis Group at the Centers for Medicare and Medicaid Services (CMS) requested this report from The Technology Assessment Program (TAP) at the Agency for Healthcare Research and Quality (AHRQ). AHRQ assigned this report to the Duke Evidence-based Practice Center (Contract No. HHSA 290-2007-10066I). The purpose of the technology assessment is to summarize the available clinical and scientific evidence on ECG-based signal analysis technologies for evaluating patients with suspected CAD. Some ECG-based technologies have been used for other purposes (e.g., detection of malignant arrhythmias), but these are not the focus of the current report. Rather, this report will concentrate on commercially available ECG-based signal analysis technologies to inform AHRQ and CMS about the utility of these emerging technologies for diagnosing CAD.
|
| 520 |
|
|
|a While chest pain is a common symptom of patients presenting to clinics and emergency wards, only about six percent of patients presenting to the emergency room with acute chest pain are ultimately diagnosed with myocardial infarction. Identification of which patients with chest pain are experiencing myocardial ischemia or infarction is critical, since a delay in diagnosis can impede the application of effective therapies, such as thrombolytic agents or percutaneous coronary intervention (PCI). Tests that identify patients with significant coronary artery disease (CAD) serve as a means of facilitating aggressive implementation of secondary preventive strategies. Thus, accurate diagnostic tests and protocols are imperative in order to properly triage patients presenting with chest pain.
|